Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, PhD, alongside a group of world-leading cancer biologists including Dr. Lewis Cantley, the discoverer of the PI3K pathway.
WHO WE ARE
Our core conviction — that simultaneously targeting multiple nodes of a biological pathway could produce a more effective therapy than targeting a single node alone — has been the foundation of our approach since the company's founding.
In February 2026, Faeth was acquired by Sensei Biotherapeutics in a transaction that included a concurrent $200 million private placement. PIKTOR is now the combined company's lead program.
OUR HISTORY
2019
Founded
Faeth Therapeutics established around the hypothesis that simultaneously suppressing multiple nodes of a pathway produces deeper, more durable tumor suppression than targeting any single node alone. Begin work on the PAM (PI3K/AKT/mTOR) pathway.
2019
Founded
Faeth Therapeutics established around the hypothesis that simultaneously suppressing multiple nodes of a pathway produces deeper, more durable tumor suppression than targeting any single node alone. Begin work on the PAM (PI3K/AKT/mTOR) pathway.
2021
First-in-human combination data
Serabelisib in-licensed. Initial clinical evidence for serabelisib combination regimens. Early signs of more complete pathway suppression.
2021
First-in-human combination data
Serabelisib in-licensed. Initial clinical evidence for serabelisib combination regimens. Early signs of more complete pathway suppression.
2022
Multi-node strategy supported
Preclinical data from Faeth and early clinical data from the investigator-initiated Phase 1b Study X31025 suggest that vertical PAM blockade — upstream and downstream simultaneously — reduces feedback-driven resistance while improving tolerability.
2022
Multi-node strategy supported
Preclinical data from Faeth and early clinical data from the investigator-initiated Phase 1b Study X31025 suggest that vertical PAM blockade — upstream and downstream simultaneously — reduces feedback-driven resistance while improving tolerability.
2023
PIKTOR program established
Sapanisertib in-licensed. Combination of serabelisib (PI3K-alpha) and sapanisertib (mTORC1/2) advanced as lead oral program targeting three PAM pathway nodes.
2023
PIKTOR program established
Sapanisertib in-licensed. Combination of serabelisib (PI3K-alpha) and sapanisertib (mTORC1/2) advanced as lead oral program targeting three PAM pathway nodes.
2025
Phase 2 endometrial cancer study initiated
Faeth initiates Phase 2 PIK-201 study with the PIKTOR regimen in advanced or recurrent endometrial cancer.
2025
Phase 2 endometrial cancer study initiated
Faeth initiates Phase 2 PIK-201 study with the PIKTOR regimen in advanced or recurrent endometrial cancer.
2026
Faeth goes public
Faeth goes public via a reverse merger with Sensei Biotherapeutics. $200M concurrent private placement. PIKTOR becomes the lead clinical program under the combined publicly-traded entity.
2026
Faeth goes public
Faeth goes public via a reverse merger with Sensei Biotherapeutics. $200M concurrent private placement. PIKTOR becomes the lead clinical program under the combined publicly-traded entity.
Now
Continue to evolve
Under the combined company, PIKTOR advances through clinical development while the pipeline expands into new indications and targets.
Now
Continue to evolve
Under the combined company, PIKTOR advances through clinical development while the pipeline expands into new indications and targets.
LEADERSHIP TEAM
BOARD OF DIRECTORS
SCIENTIFIC FOUNDERS
GET IN TOUCH
Whether you're a potential partner, investor, physician, researcher, or just curious about our work — we'd love to connect. Fill out the form and the right person on our team will follow up.
For patient and clinical trial inquiries, please visit our Patients page.
FAETH
The drug product candidates described on this website are investigational agents that have not been approved by the Food and Drug Administration or any other regulatory authority. Their safety and efficacy have not been established.
